Diagnostic performance of EUS in predicting advanced cancer among patients with Barrett’s esophagus and high-grade dysplasia/early adenocarcinoma: systematic review and meta-analysis

Qumseya, Bashar J.; Brown, John F.; Abraham, Merna; White, Donna L.; Wolfsen, Herbert C.; Gupta, Neil; Vennalaganti, Prashanth; Sharma, Prateek; Wallace, Michael B.

doi:10.1016/j.gie.2014.08.025

Cited by 39 publications

(28 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The depth of Barrett's esophageal adenocarcinoma is difficult to diagnose with white light endoscopy [19], and even with the use of EUS and NBI. A recent meta-analysis has shown that detection of lesions with T1sm or deeper invasion by EUS had a sensitivity of 56% and specificity of 89% [20]. We also reported that the accuracy for NBI-ME in detecting T1sm or deeper invasion was 72% [21].…”

Section: Discussionmentioning

confidence: 99%

Treatment Outcomes of Endoscopic Submucosal Dissection for Adenocarcinoma Originating from Long-Segment Barrett’s Esophagus versus Short-Segment Barrett’s Esophagus

et al. 2018

View full text Add to dashboard Cite

Background: In recent years, effective outcomes of endoscopic submucosal dissection (ESD) for esophagogastric junction cancer including short-segment Barrett’s esophagus (SSBE) cancer have been reported. However, the efficacy of ESD for long-segment Barrett’s esophagus (LSBE) cancer is unknown. Aim: To clarify the treatment outcomes of ESD for LSBE cancer versus SSBE cancer. Methods: A total of 86 patients with 91 superficial Barrett’s esophageal adenocarcinomas who underwent ESD were enrolled; of these, 68 had underlying SSBE and 18 had LSBE. Procedure outcomes and prognosis were compared. Results: There was no significant difference in age and tumor diameter among patients. The only complication observed was stricture, but it was not significant (2 vs. 9%). No significant difference was observed in the negative horizontal margin rates (94.1 vs. 95.7%), R0 resection rates (83.8 vs. 82.6%), curative resection rates (72.1 vs. 73.9%), and noncurative factors. Both LSBE and SSBE cancer showed favorable 3-year overall survival rates (95.0 vs. 94.4%) in the median observation period of 28.5 months. Conclusions: ESD for LSBE cancer achieved procedure outcomes and short-term prognosis comparable to SSBE. ESD has the potential to be an effective therapeutic option for esophageal neoplasms in patients with LSBE.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment Outcomes of Endoscopic Submucosal Dissection for Adenocarcinoma Originating from Long-Segment Barrett’s Esophagus versus Short-Segment Barrett’s Esophagus

et al. 2018

View full text Add to dashboard Cite

show abstract

“…This is consistent with other studies documenting the limited accuracy of endoscopic ultrasonography in staging early IMC and HGD. 17,18 Radiofrequency ablation was offered selectively to patients with long-segment BE after nodular regions were pathologically assessed by EMR. We chose to refer these patients for ablation, as serial EMR of long-segment BE has been associated with a higher rate of postoperative strictures, ranging from 37%-86%.…”

Section: Discussionmentioning

confidence: 99%

Endoscopic mucosal resection for high-grade dysplasia and intramucosal carcinoma: a Canadian experience

Yamashita

Bethune³

et al. 2017

CJS

View full text Add to dashboard Cite

Background: Endoscopic mucosal resection (EMR) is increasingly being used as a first-line treatment for Barrett esophagus (BE) with high-grade dysplasia (HGD) and intramucosal adenocarcinoma (IMC). We reviewed our experience with endoscopic treatment of BE with HGD and IMC at our institution with respect to eradication rates, complications and long-term recurrence. Methods:We performed a single-centre retrospective review of all patients referred between October 2010 and August 2014 for EMR with dysplastic BE or IMC. We performed EMR using a cap-fitted endoscope, and the procedure was repeated every 3 months until eradication or progression of disease.Results: A total of 28 patients were identified: 16 with dysplastic BE (14 HGD, 1 low-grade dysplasia, 1 intermediate dysplasia) and 12 with IMC. Complete eradication of HGD was achieved in 11 of 14 (79%) patients. Three of 12 (25%) patients initially referred with suspected IMC were found to have invasive adenocarcinoma on EMR. Eradication was successful in 8 of 9 (89%) patients with true IMC, with 1 patient progressing to salvage esophagectomy. Complications occurred in 2 of 28 (7%) patients; both had esophageal strictures managed with dilatation. Median duration of follow-up was 371 days. Conclusion:Our experience supports the safety of EMR as a first-line treatment for patients with BE with dysplasia and IMC in early short-term follow-up. Résultats : En tout, 28 patients ont été recensés : 16 présentaient un oesophage de Barrett dysplasique (14 DHG, 1 dysplasie de bas grade, 1 dysplasie intermé-diaire) et 12 présentaient un adénocarcinome intramuqueux. Une éradication complète de la DHG a été obtenue chez 11 patients sur 14 (79 %). Chez 3 patients sur 12 (25 %) initialement adressés pour un adénocarcinome intramuqueux, la mucosectomie a révélé un adénocarcinome envahissant. Huit patients sur 9 (89 %) atteints d'un adénocarcinome intramuqueux avéré ont subi le traitement d'éradication avec succès, et 1 patient a dû subir une oesophagectomie de sauvetage. Des complications sont survenues chez 2 patients sur 28 (7 %); les 2 patients ont présenté des sténoses oesophagiennes corrigées par dilatation. La durée médiane du suivi a été de 371 jours. Conclusion :Notre expérience confirme l'innocuité de la mucosectomie endoscopique comme traitement de première intention chez les patients présentant un oesophage de Barrett dysplasique ou un adénocarcinome intramuqueux dans le contexte d'un suivi à court terme.

show abstract

“…Furthermore, EUS identified advanced disease in 4% of patients with no endoscopically visible nodules. [62] …”

Section: Early Esophageal Cancermentioning

confidence: 99%

Esophageal Cancer

Khanna¹,

Lightdale²

2015

ERCP and EUS

View full text Add to dashboard Cite

Diagnostic performance of EUS in predicting advanced cancer among patients with Barrett’s esophagus and high-grade dysplasia/early adenocarcinoma: systematic review and meta-analysis

Cited by 39 publications

References 32 publications

Treatment Outcomes of Endoscopic Submucosal Dissection for Adenocarcinoma Originating from Long-Segment Barrett’s Esophagus versus Short-Segment Barrett’s Esophagus

Treatment Outcomes of Endoscopic Submucosal Dissection for Adenocarcinoma Originating from Long-Segment Barrett’s Esophagus versus Short-Segment Barrett’s Esophagus

Endoscopic mucosal resection for high-grade dysplasia and intramucosal carcinoma: a Canadian experience

Esophageal Cancer

Contact Info

Product

Resources

About